Lanier Biotherapeutics develops antibody treatments targeting immune checkpoint inhibitor pneumonitis and type 2 inflammation-related diseases, such as asthma and atopic dermatitis. Their therapies aim to mitigate pulmonary fibrosis and improve health outcomes for patients with limited responses to existing corticosteroid treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatment options for immune checkpoint inhibitor pneumonitis (CIP) and type 2 inflammation-related diseases, such as asthma and atopic dermatitis, often have limited efficacy, particularly in patients with moderate-to-severe conditions or those who do not respond well to corticosteroids. These patients face significant morbidity, including pulmonary fibrosis and impaired quality of life. There is a need for more targeted and effective therapies to address these inflammatory conditions.
Solution
Lanier Biotherapeutics is developing a portfolio of antibody treatments designed to address unmet needs in immune-mediated diseases. Their lead programs focus on immune checkpoint inhibitor pneumonitis (CIP) and type 2 inflammation/fibrosis. The company's approach involves discovering and developing novel antibody therapeutics that can restore immune balance and mitigate the underlying causes of inflammation and fibrosis. Lanier Biotherapeutics' therapies aim to provide protection from pulmonary fibrosis, amplify tumor suppression in CIP, and address moderate-to-severe conditions like asthma and atopic dermatitis with limited response to corticosteroid treatment. They are also developing biobetter multifunctional anti-VEGF antibodies for retinal diseases.
Target Audience
The primary target audience includes patients suffering from immune checkpoint inhibitor pneumonitis, type 2 inflammation-related diseases such as asthma and atopic dermatitis, and retinal diseases, as well as the physicians who treat these conditions.
Features
- Antibody therapeutics targeting immune checkpoint inhibitor pneumonitis (CIP) to protect from pulmonary fibrosis and amplify tumor suppression.
- Antibody therapeutics for Type 2 Inflammation / Fibrosis, addressing conditions like asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis and food allergies.
- Development of biobetter multifunctional anti-VEGF antibodies for retinal diseases.